bizelesin
Small moleculeexperimental
The duocarmycins are members of a series of related natural products first isolated from Streptomyces bacteria in 1978. They are notable for their extreme cytotoxicity and thus represent a class of exceptionally potent antitumour antibiotics. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1997 (NCT00003021)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1- Mol. weight
- 815.72 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDuocarmycin ↗
- ChEMBLCHEMBL284642 ↗
Also known as
- benzo(1,2-b:4,3-b')dipyrrol-4-ol, 6,6'-(carbonylbis(imino-1h-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (s-(r*,r*)))
- bizelesin
- bizelesin
- bizelesin
- bizelesin
- bizelesin
- u 77779
- u-77779
- u-77779
- u-77779
- u-77,779
- u-78779
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003021 | Phase 1 | Aug 1, 1997 | National Cancer Institute (NCI), University of Texas, San Antonio |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 1997 |
2 organizations
Page 1 / 1